急性脑梗死发病时间与纤维蛋白原分子活性的相关性研究

Study of correlation between times of a disease and plasma fibrinogen molecular reactivity in patients with acute cerebral infarction

1目的 分析急性脑梗死患者血浆纤维蛋白原含量及分子活性的变化及其与有关临床指标的相关性。 2方法 选取急性脑梗死患者 14 3例 ,随机分为非溶栓治疗组 70例 ;溶栓治疗组 6 3例 ;一过性脑缺血发作患者 ( TIA) 31例 ;病例对照组 30例。在不同时间测定 FMPV、Fg、FMPV/ ODmax血小板粘附率。3结果 FMPV在 4组间比较差异有显著性 ( P<0 .0 1) ,急性脑梗死非溶栓组显著高于 TIA组 ( P<0 .0 1) ,Fg在急性脑梗死组明显高于 TIA及病例对照组 ( P<0 .0 1)。持续静脉溶栓治疗可降低急性脑梗死发病 1周左右 FMPV、FMPV/ ODmax及血小板粘附率。 4结论 Fg升高是急性脑梗死的病理基础之一 ,持续静脉溶栓治疗是有效的治疗方法 ,同时应监测纤维蛋白原含量和分子活性 ,并及时应用抗血小板粘附聚集药物 ,以防再梗死的发生。

Objective To explore correlation among times of cerebral infarction and fibrinogen molecular reactivity in plasma,clinical factor in the patients with cerebral infarction.Methods FMPV,Fg,FMPV/OD max platelet adhibit rate were measured in 143 patients with acute cerebral infarction,(divided randomly into NTT and TT groups),31 cases with TIA and 30 cases contrast group(DCG).Results FMPV was significant difference among four groups(P<0.01),the NTT group was remarkably higher than TIA group (P<0.01),Fg was raised in TT as compared with TIA and DCG (P<0.01),continuous thrombolytic treatment could make FMPV,FMPV/OD max platelet adhibit rat reduce.Conclusions It indicated that hyperfibrinemia in plasma is one of pathologic basis of the ACI,continuous thrombolytic therapy is effective to ACI.fibrinogen and its molucular reactivity should be monitored at same times.The anti-platelet aggregation drugs should be administed in order to prevent from cerebral infarction again.